Semliki Forest virus‐mediated gene therapy of the RG2 rat glioma

摘要: F. P. Roche, B. J. Sheahan, S. M. O'Mara and G. Atkins (2010) Neuropathology Applied Neurobiology36, 648–660 Semliki Forest virus-mediated gene therapy of the RG2 rat glioma Aims: Glioblastoma multiforme is most common malignant adult brain tumour. Despite numerous advances in cancer there has been little change prognosis glioblastoma multiforme, which remains invariably fatal. We examined virus virus-like particle (SFV VLP) expression system encoding interleukin-12 (IL-12) as a therapeutic intervention against syngeneic glioma model. Methods: Glioma-bearing rats were treated with IL-12-encoding SFV VLPs via an implanted cannula. Animals 5 × 107 (low-dose) or 5 × 108 (high-dose) per treatment effect on growth survival was assessed. Results: Low-dose produced 70% reduction tumour volume, associated significant extension (20.45%) that dependent upon IL-12 expression. High-dose resulted 87% related to oncolytic capacity VLP system. delivery central nervous (CNS) demonstrated potential vector induce lethal pathology unrelated replication-competent high-level Treatment-related death pronounced high dose-treated animals appeared be result inflammation, necrosis oedema at inoculation site. Conclusion: The efficacy approach for model addition this, broad tropism SFV-based may limit use CNS unless this inherent limitation can overcome.